Targeted therapy for cancer of unknown primary
A few people with cancer of unknown primary (CUP) will have targeted therapy. It uses drugs to target specific molecules (such as proteins) on or inside cancer cells. These molecules help send signals that tell cells to grow or divide. By targeting these molecules, the drugs stop the growth and spread of cancer cells while limiting harm to normal cells. Targeted therapy may also be called molecular targeted therapy.
You may have targeted therapy to:
- kill cancer cells
- relieve pain or control the symptoms of advanced CUP (called palliative therapy)
Your healthcare team will consider your personal needs to plan the drugs, doses and schedules of targeted therapy. You may also receive other treatments.
Targeted therapy drugs used for CUP @(Model.HeadingTag)>
The drugs that may be offered to people with neuroendocrine carcinoma of unknown primary are:
- sunitinib (Sutent)
- everolimus (Afinitor)
Researchers are still looking at how effective certain targeted therapy drugs might be against other types of CUP.
Side effects @(Model.HeadingTag)>
Side effects can happen with any type of treatment for CUP, but everyone’s experience is different. Some people have many side effects. Other people have few or none at all.
Targeted therapy doesn’t usually damage healthy cells, so it tends to cause fewer and less severe side effects than chemotherapy and radiation therapy. Chemotherapy and radiation therapy can damage healthy cells along with cancer cells.
If side effects develop with targeted therapy, they can happen any time during, immediately after or a few days or weeks after targeted therapy. Sometimes late side effects develop months or years after targeted therapy. Most side effects go away on their own or can be treated, but some side effects may last a long time or become permanent.
Side effects of targeted therapy will depend mainly on the type of drug or combination of drugs, the dose, how it’s given and your overall health. Some common side effects of targeted therapy are:
Tell your healthcare team if you have these side effects or others you think might be from targeted therapy. The sooner you tell them of any problems, the sooner they can suggest ways to help you deal with them.
Information about specific cancer drugs @(Model.HeadingTag)>
Cancer Care Ontario. Drug Formulary. Toronto, ON: Cancer Care Ontario;
Fizazi K, Greco FA, Pavlidis N, et al . Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. Oxford University Press; 2011.
Greco FA & Hainsworth JD . Cancer of unknown primary site. DeVita VT Jr, Lawrence TS, & Rosenberg SA. Cancer: Principles & Practice of Oncology. 10th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2015: 113:1720-1737.
Hainsworth JD, Greco FA . Chemotherapy of carcinoma of unknown primary site. Perry MC, Doll DC, Freter CE. Perry's The Chemotherapy Source Book. 5th ed. Lippincott Williams Wilkins; 2012: Chapter 37. http://www.lwwoncology.com.
Macmillan Cancer Support. Cancer of unknown primary (CUP). London, UK: Macmillan Cancer Support; 2014: http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Unknownprimary/Unknownprimary.aspx.
National Comprehensive Cancer Network. Occult Primary (Cancer of Unknown Primary [CUP]) (Version 3.2014). http://www.nccn.org/professionals/physician_gls/pdf/occult.pdf.